Clinical Trial Update: Evaluation of Efficacy and Safety of Rituximab and Mycophenolate Mofetil Combination in Patients With Interstitial Lung Disease Related to Systemic Sclerosis [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial is evaluating the combination of rituximab and mycophenolate mofetil for systemic sclerosis–associated interstitial lung disease; the s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis-associated Interstitial Lung Disease

Drugs mentioned

• CELLCEPT (mycophenolate mofetil hydrochloride)
• Rituxan (rituximab)

Snippet

Sponsor: University Hospital, Tours | Conditions: Interstitial Lung Disease With Systemic Sclerosis | Phase 3 | Status: NOT_YET_RECRUITING